Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Epiminder Ltd. ( (AU:EPI) ) has issued an announcement.
Epiminder Ltd., a Melbourne-based medical device and information solutions company, specialises in diagnostic and treatment technologies for epilepsy and other seizure disorders that require continuous monitoring. Backed by founding partners including the Bionics Institute, St Vincent’s Hospital, the University of Melbourne and Cochlear Limited, it operates in Australia and the United States and has developed Minder, a minimally invasive device for long-term electrographic brain monitoring.
The company announced that it will release its financial results for the six months ended 31 December 2025 on 25 February 2026 and will host an investor webinar that morning to discuss the 1H FY26 performance. The update signals Epiminder’s ongoing efforts to engage current and prospective investors as it advances its epilepsy monitoring technology, with the upcoming results likely to offer insight into commercial progress and operational momentum for its Minder platform.
More about Epiminder Ltd.
Epiminder Ltd. is a Melbourne-headquartered medical device and information solutions company focused on diagnostic and treatment tools for epilepsy and other seizure disorders that require continuous monitoring. Founded in 2017 with partners including the Bionics Institute, St Vincent’s Hospital, the University of Melbourne and Cochlear Limited, it operates in Australia and the United States and develops minimally invasive brain monitoring technology such as its Minder device.
Minder is a minimally invasive, continuous electrographic brain monitoring device designed to provide epilepsy patients and clinicians with detailed data on brain activity over extended periods. By enabling long-term monitoring in everyday environments rather than controlled clinical settings, Minder supports remote assessment of disease progression and the effectiveness of drug therapies and other interventions.
Average Trading Volume: 189,867
For an in-depth examination of EPI stock, go to TipRanks’ Overview page.